View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPLx Pharma Winddown 과거 순이익 실적과거 기준 점검 0/6PLx Pharma Winddown은 연평균 54.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 31.3%의 비율로 감소했습니다.핵심 정보54.57%순이익 성장률68.03%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-31.31%자기자본이익률-104.74%순이익률-606.91%최근 순이익 업데이트30 Sep 2022최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.공시 • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.공시 • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.공시 • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.Seeking Alpha • Aug 12PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48MPLx Pharma press release (NASDAQ:PLXP): Q2 Non-GAAP EPS of -$0.52 misses by $0.02. Revenue of $0.48M. Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.분석 기사 • May 10Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.Recent Insider Transactions • Mar 24Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 21Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 18Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.분석 기사 • Nov 03Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is ReasonableDespite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...분석 기사 • Sep 23We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...Seeking Alpha • Sep 17PLx Pharma: First Commercial Launch Makes It AttractivePLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.Recent Insider Transactions • Jun 16Executive Chairman recently bought US$100k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly US$12.48 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of US$300k worth in shares.분석 기사 • Jun 15PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, PLx Pharma...Major Estimate Revision • May 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.82 to -US$1.29 per share. Revenue forecast of US$7.27m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$16.00 unchanged from last update. Share price rose 2.9% to US$11.39 over the past week.Major Estimate Revision • Mar 19Consensus revenue estimates increase to US$6.80mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$1.40m to US$6.80m. Forecast losses expected to reduce from -US$1.12 to -US$1.03 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$12.00 unchanged from last update. Share price rose 27% to US$10.07 over the past week.Analyst Estimate Surprise Post Earnings • Mar 14Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 100% compared to a 22% growth forecast for the Pharmaceuticals industry in the US.Recent Insider Transactions • Mar 10Executive Chairman recently bought US$200k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly US$8.00 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.분석 기사 • Mar 05Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Is New 90 Day High Low • Feb 10New 90-day high: US$6.89The company is up 99% from its price of US$3.47 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: US$6.50The company is up 103% from its price of US$3.21 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 14Earnings miss expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 1,828%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US.Is New 90 Day High Low • Nov 14New 90-day high: US$4.31The company is up 29% from its price of US$3.35 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역PLx Pharma Winddown가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PLXP.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 225-2862330 Jun 2211-4164331 Mar 2210-4856431 Dec 218-4940430 Sep 217-6122530 Jun 210-4313431 Mar 210-309531 Dec 200-179430 Sep 200-1110430 Jun 200-610431 Mar 200-1010431 Dec 191-3410530 Sep 191-299530 Jun 191-348531 Mar 191-288431 Dec 18118430 Sep 181-108530 Jun 181-109531 Mar 181-911531 Dec 171-1510430 Sep 170-910230 Jun 170-68131 Mar 170-55031 Dec 160-55030 Sep 160-44030 Jun 160-53031 Mar 160-42031 Dec 150-42030 Sep 150-42130 Jun 150-32131 Mar 150-42231 Dec 140-52331 Dec 131-946양질의 수익: PLXP.Q 은(는) 현재 수익성이 없습니다.이익 마진 증가: PLXP.Q는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 PLXP.Q의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PLXP.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PLXP.Q은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PLXP.Q는 현재 수익성이 없으므로 자본 수익률이 음수(-104.74%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/04 01:22종가2023/09/29 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PLx Pharma Winddown Corp.는 6명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kenneth TrbovichBrean Capital Historical (Janney Montgomery)Hamed KhorsandBWS Financial Inc.Jason ButlerCitizens JMP Securities, LLC3명의 분석가 더 보기
공시 • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
공시 • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.
공시 • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.
공시 • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.
Seeking Alpha • Aug 12PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48MPLx Pharma press release (NASDAQ:PLXP): Q2 Non-GAAP EPS of -$0.52 misses by $0.02. Revenue of $0.48M. Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.
분석 기사 • May 10Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.
Recent Insider Transactions • Mar 24Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 21Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 18Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
분석 기사 • Nov 03Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is ReasonableDespite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...
분석 기사 • Sep 23We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...
Seeking Alpha • Sep 17PLx Pharma: First Commercial Launch Makes It AttractivePLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.
Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.
Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.
Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.
Recent Insider Transactions • Jun 16Executive Chairman recently bought US$100k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly US$12.48 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of US$300k worth in shares.
분석 기사 • Jun 15PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, PLx Pharma...
Major Estimate Revision • May 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.82 to -US$1.29 per share. Revenue forecast of US$7.27m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$16.00 unchanged from last update. Share price rose 2.9% to US$11.39 over the past week.
Major Estimate Revision • Mar 19Consensus revenue estimates increase to US$6.80mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$1.40m to US$6.80m. Forecast losses expected to reduce from -US$1.12 to -US$1.03 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$12.00 unchanged from last update. Share price rose 27% to US$10.07 over the past week.
Analyst Estimate Surprise Post Earnings • Mar 14Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 100% compared to a 22% growth forecast for the Pharmaceuticals industry in the US.
Recent Insider Transactions • Mar 10Executive Chairman recently bought US$200k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly US$8.00 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
분석 기사 • Mar 05Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Is New 90 Day High Low • Feb 10New 90-day high: US$6.89The company is up 99% from its price of US$3.47 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: US$6.50The company is up 103% from its price of US$3.21 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 14Earnings miss expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 1,828%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US.
Is New 90 Day High Low • Nov 14New 90-day high: US$4.31The company is up 29% from its price of US$3.35 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.